Skip to main content

Articles

Payers' Guide, FDA Approvals

Eylea (Aflibercept) Receives FDA Approval of New Dose for Age-Related Macular Degeneration

Payers' Guide, FDA Approvals

Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura

Payers' Guide, FDA Approvals

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Payers' Guide, FDA Approvals

Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia

Payers' Guide, FDA Approvals

Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults

Payers' Guide, FDA Approvals

Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation

FDA Approvals, Payers' Guide

FDA Approvals of Novel Brand-Name Prescription Drugs in 2018

Payers' Guide, FDA Approvals

Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma

Payers' Guide, FDA Approvals

Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis

FDA Approvals, Oncology Overview, Payers' Guide, Oncology

New Indications Approved by the FDA in 2018 for Oncology Drugs

Page 56 of 244
Results 551 - 560 of 2436